Mitigating retinitis pigmentosa based on a non-invasive rod energy-landscape biomarker
Mitigating retinitis pigmentosa based on a non-invasive rod energy-landscape biomarker
批准号:
10733154
负责人:
BRUCE A. BERKOWITZ
金额:
$50.18万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-30 至 2027-06-30
关键词:
AccelerationAddressAtrophicBiological AssayBiological MarkersBlindnessCell Culture TechniquesCessation of lifeClinicClinical TreatmentConeDarknessDietDiseaseEarly DiagnosisEcosystemElectron MicroscopyEtiologyEvolutionExperimental ModelsExposure toFriendsFunctional disorderFutureGenesGeneticHistologicHourInheritedKnowledgeLightMeasurementMeasuresMethylene blueMitochondriaMouse StrainsMusMutationNamesNatural HistoryNuclear Hormone ReceptorsOnset of illnessOptical Coherence TomographyOxygen ConsumptionPathogenicityPathologyPatient-Focused OutcomesPatientsPerformancePeriodicityPrediction of Response to TherapyPublic HealthReceptor GeneReportingResearchRetinitis PigmentosaRodShapesSignal TransductionSynthetic ProgestogensTechnologyTestingTimeTissuesTransducinTreatment EfficacyTreatment outcomeUp-RegulationVertebrate PhotoreceptorsVisionWild Type Mousealpha Subunit Transducinbench to bedsidebiomarker performanceclinically relevantdark rearingexperimental studyhuman modelimaging biomarkerimaging modalityimprovedimproved outcomeindexinginnovationloss of function mutationmitochondrial dysfunctionneuroprotectionnon-invasive imagingnovelpersonalized managementphosphodiesterase 6phosphoric diester hydrolasephotoreceptor degenerationpostnatalpreventrestorationretinal rodstranslational barrier
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary / Abstract: Retinitis pigmentosa (RP) is a disease that leads to untreatable and
irreversible cone death and blindness. A myriad of loss-of-function mutations, including in transducin 1 or
phosphodiesterase 6 genes, underlie RP. Ex vivo studies from experimental models support abnormal
mitochondria performance as a common pathogenic condition leading to RP pathology. However,
evaluating such mitochondrial abnormalities in patients is not possible and a one-therapy-fits-all approach
is unlikely to improve outcomes patient diversity. Addressing these major knowledge gaps will require a
patient-friendly, non-invasive biomarker of mitochondria performance.
Recently, we discovered a novel index of mitochondria performance based on a feature that is
readily identifiable in optical coherence tomography (OCT), the inner segment ellipsoid zone (ISez). Our
first-in-kind studies in wild-type mice show that the shape of the ISez profile changes from elongated
during a low energy demand condition (light) to rounder during a high energy demand condition (dark).
The underlying mitochondria etiology of the change in ISez profile shape is supported by electron
microscopy and oxygen consumption rate measurements in two mice strains with distinct mitochondria
activity. For example, OCT examination of cyclic-light reared 2-month-old mice with a mutation in the α
subunit of transducin 1 (Gnat1rd17) shows modest rod loss with a rounder-than-normal ISez and higher rate
of oxygen consumption than in the dark, biomarker evidence for early mitochondria overperformance.
Also, at postnatal (P) day 23, dark-reared mice with a mutation in the rod phosphodiesterase 6b gene
(Pde6brd10) show modest rod loss together with rounder-than-normal ISez when examined in the dark,
biomarker evidence for mitochondria overperformance. When P23 dark-reared Pde6brd10 mice are
exposed to room light for 1 hour they showed a more-elliptical-than-normal ISez shape suggesting rod
mitochondria underperformance. This is notable because, whilst the 1 hour of light did not cause
immediate additional rod death, accelerated rod loss reportedly occurs days later after continued dark-
rearing. These considerations show that the ISez profile shape is sensitive to abnormalities in the rod
energy landscape that precede later rod loss. The natural history of change of the ISez profile shape as it
relates to rod atrophy in cyclic-light reared Gnat1rd17 or Pde6brd10 mice is unknown.
Our working hypothesis is that restoring our mitochondria performance biomarker (the ISez profile
shape) to wild-type-like levels predicts pro-survival treatment outcomes in experimental IRD. These
studies introduce an innovative and clinically relevant imaging biomarker, the ISez profile shape, for
assessing treatment efficacy in RP/IRD. Therapies that restore the ISez profile shape to normal are
ultimately expected to prevent loss of sight in patients with IRD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Early Retinal Imaging Biomarkers for Treating Later Spatial Memory Loss in Experimental Alzheimer's Disease
-
批准号:10650636
-
项目类别:
-
资助金额:$113.56万
-
财政年份:2023
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
Novel Imaging Biomarker for Treating Spatial Memory Loss in Prodromal Alzheimer's Disease Models
-
批准号:9925773
-
项目类别:
-
资助金额:$55.87万
-
财政年份:2017
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
Novel Imaging Biomarker for Treating Spatial Memory Loss in Prodromal Alzheimer's Disease Models
-
批准号:10165441
-
项目类别:
-
资助金额:$55.87万
-
财政年份:2017
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
Role of calcium channels in the development of diabetic retinopathy
-
批准号:8635018
-
项目类别:
-
资助金额:$19.0万
-
财政年份:2014
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
Manganese-enhanced MRI Studies of Retinal Neovascularization
-
批准号:7404426
-
项目类别:
-
资助金额:$22.12万
-
财政年份:2007
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
Manganese-enhanced MRI Studies of Retinal Neovascularization
-
批准号:7237746
-
项目类别:
-
资助金额:$18.81万
-
财政年份:2007
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
Retinal Oxygenation in Diabetic Retinopathy
-
批准号:6640274
-
项目类别:
-
资助金额:$25.9万
-
财政年份:2002
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
Retinal Oxygenation in Diabetic Retinopathy
-
批准号:6544442
-
项目类别:
-
资助金额:$24.22万
-
财政年份:2002
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
Retinal Oxygenation in Diabetic Retinopathy
-
批准号:6776347
-
项目类别:
-
资助金额:$41.07万
-
财政年份:2002
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
NMR STUDIES OF PRERETINAL NEOVASCULARIZATION
-
批准号:2163944
-
项目类别:
-
资助金额:$22.46万
-
财政年份:1995
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
NMR STUDIES OF PRERETINAL NEOVASCULARIZATION
-
批准号:2163946
-
项目类别:
-
资助金额:$23.68万
-
财政年份:1995
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
NMR STUDIES OF PRERETINAL NEOVASCULARIZATION
-
批准号:2378088
-
项目类别:
-
资助金额:$24.75万
-
财政年份:1995
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
MR STUDIES OF EXPERIMENTAL RETINOPATHY OF PREMATURITY
-
批准号:2888427
-
项目类别:
-
资助金额:$26.8万
-
财政年份:1995
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
NMR STUDIES OF PRERETINAL NEOVASCULARIZATION
-
批准号:2163945
-
项目类别:
-
资助金额:$1.62万
-
财政年份:1995
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
MR STUDIES OF EXPERIMENTAL RETINOPATHY OF PREMATURITY
-
批准号:6179981
-
项目类别:
-
资助金额:$20.5万
-
财政年份:1995
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
MR STUDIES OF EXPERIMENTAL RETINOPATHY OF PREMATURITY
-
批准号:6384376
-
项目类别:
-
资助金额:$21.59万
-
财政年份:1995
-
负责人:BRUCE A. BERKOWITZ
-
依托单位:
海外基金